In the past two decades, drugs newly approved by the FDA have been associated with an increasing number of expedited development or review programs. Though expedited programs should be strictly limited to drugs providing noticeable clinical advances, this trend is being driven by drugs that are not first in class and thus potentially less innovative.
No takes yet. Share an insight, caveat, or question.
Kesselheim et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: